Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD) is a chronic disease of the gastrointestinal tract that is characterised by intermittent episodes of remission and relapse. BIOHIT HealthCare has academic and clinical interests in pursuing novel techniques and strategies for personalising the management of IBD. Personalising the management of Crohn's disease and Ulcerative Colitis has the potential to bring about long-term successful outcomes for the diseases that will benefit both patients and healthcare systems.
BIOHIT's interests in IBD cover:
Prediction of relapse
Monitoring therapy success
Identifying deep remission
Biological therapeutic drug monitoring and applications
Improving patient outcomes/quality of life
Leveraging In vitro parameters that help achieve the above
Monitor disease activity
Diagnose with confidence
Select optimal therapy
Reduce referrals and admissions
BIOHIT HealthCare in IBD
Crohn's Disease (CD) and Ulcerative colitis (UC) are two types of IBD that require a great deal of clinical and financial input to gain and retain control of these chronic inflammatory diseases. There is currently a great deal of interest in how in vitro diagnostics can help clinicians understand the mechanisms of the diseases as well as help improve the management of the conditions. This too requires a dedicated and systematic approach with good support from a wide range of stakeholders, and often this begins with a collaboration between industry and healthcare providers.
BIOHIT HealthCare helps support clinical research in IBD and supplies novel tests that promise to help diagnose, predict and monitor IBD sooner, faster and cost effectively. Right now BIOHIT is working closely with clinical teams around the UK to bring testing closer to the patient, providing patients with reassurance, independence and confidence. For example, home testing through telemedicine programs that enable the combination of Calprotectin testing with smartphone technology gives patients the ability to test their faecal calprotectin levels anywhere in the world by using QuantOn Cal. This way IBD teams can monitor the disease progression of selected patients remotely and proactively without the patient needing to visit the hospital or clinic.
Similarly, there is an emerging role for therapeutic drug monitoring in IBD - that is testing the serum levels of biological drugs such as anti-TNFa blockers and anti-Integrin blockers to provide valuable information about drug efficacy. The increasing popularity of biosimilars, the challenges of switching biologics, the advent of new biological drugs, and the introduction of biobetters all require a more personalised approach to IBD management. Recent advances in the application of Therapeutic drug monitoring assays means that clinicians now have an additional set of tools that can help identify, predict, and manage loss of response in symptomatic patients on e.g. Infliximab, Adalimumab, Ustekinumab, Golimumab and Vedolizumab. This has been made possible thanks to the increasing amount of evidence substantiating the benefits of using e.g. IDKmonitor assays in routine clinical care from UK IBD cohorts.
Looking to the future, faecal tests have a large role to play in the investigation of IBD. Gut microbiota analysis from faecal samples promises to help identify patients who are likely to respond to particular therapies according to their gut microbial makeup, and BIOHIT remains at the forefront of technological delivery with its CE marked gut microbiota test "GA-Map Dysbiosis Test".
If you would like to know more about BIOHIT HealthCare in the field of IBD please get in touch.